174 related articles for article (PubMed ID: 33648940)
21. Randomized double-blind trial of sulindac and etodolac to eradicate aberrant crypt foci and to prevent sporadic colorectal polyps.
Takayama T; Nagashima H; Maeda M; Nojiri S; Hirayama M; Nakano Y; Takahashi Y; Sato Y; Sekikawa H; Mori M; Sonoda T; Kimura T; Kato J; Niitsu Y
Clin Cancer Res; 2011 Jun; 17(11):3803-11. PubMed ID: 21385928
[TBL] [Abstract][Full Text] [Related]
22. Chromoendoscopy with a Standard-Resolution Colonoscope for Evaluation of Rectal Aberrant Crypt Foci.
Kowalczyk M; Siermontowski P; Mucha D; Ambroży T; Orłowski M; Zinkiewicz K; Kurpiewski W; Paśnik K; Kowalczyk I; Pedrycz A
PLoS One; 2016; 11(2):e0148286. PubMed ID: 26886097
[TBL] [Abstract][Full Text] [Related]
23. Pharmacokinetics and safety of green tea polyphenols after multiple-dose administration of epigallocatechin gallate and polyphenon E in healthy individuals.
Chow HH; Cai Y; Hakim IA; Crowell JA; Shahi F; Brooks CA; Dorr RT; Hara Y; Alberts DS
Clin Cancer Res; 2003 Aug; 9(9):3312-9. PubMed ID: 12960117
[TBL] [Abstract][Full Text] [Related]
24. Rectal Aberrant Crypt Foci in Humans Are Not Surrogate Markers for Colorectal Cancer Risk.
Quintanilla I; López-Cerón M; Jimeno M; Cuatrecasas M; Zabalza M; Moreira L; Alonso V; Rodríguez de Miguel C; Muñoz J; Castellvi-Bel S; Llach J; Castells A; Balaguer F; Camps J; Pellisé M
Clin Transl Gastroenterol; 2019 Jun; 10(6):e00047. PubMed ID: 31136360
[TBL] [Abstract][Full Text] [Related]
25. Effects of dosing condition on the oral bioavailability of green tea catechins after single-dose administration of Polyphenon E in healthy individuals.
Chow HH; Hakim IA; Vining DR; Crowell JA; Ranger-Moore J; Chew WM; Celaya CA; Rodney SR; Hara Y; Alberts DS
Clin Cancer Res; 2005 Jun; 11(12):4627-33. PubMed ID: 15958649
[TBL] [Abstract][Full Text] [Related]
26. Predictive value of rectal aberrant crypt foci for intraepithelial neoplasia in ulcerative colitis - a cross-sectional study.
Freire P; Figueiredo P; Cardoso R; Manuel Donato M; Ferreira M; Mendes S; Silva MR; Cipriano MA; Ferreira AM; Vasconcelos H; Portela F; Sofia C
Scand J Gastroenterol; 2014 Oct; 49(10):1219-29. PubMed ID: 25157637
[TBL] [Abstract][Full Text] [Related]
27. Phase IB randomized, double-blinded, placebo-controlled, dose escalation study of polyphenon E in women with hormone receptor-negative breast cancer.
Crew KD; Brown P; Greenlee H; Bevers TB; Arun B; Hudis C; McArthur HL; Chang J; Rimawi M; Vornik L; Cornelison TL; Wang A; Hibshoosh H; Ahmed A; Terry MB; Santella RM; Lippman SM; Hershman DL
Cancer Prev Res (Phila); 2012 Sep; 5(9):1144-54. PubMed ID: 22827973
[TBL] [Abstract][Full Text] [Related]
28. Loss of expression of DNA mismatch repair proteins in aberrant crypt foci identified in vivo by magnifying colonoscopy in subjects with hereditary nonpolyposic and sporadic colon rectal cancer.
Ramírez-Ramírez MA; Sobrino-Cossío S; de la Mora-Levy JG; Hernández-Guerrero A; Macedo-Reyes Vde J; Maldonado-Martínez HA; Alonso-Larraga JO; Ramírez-Solis ME
J Gastrointest Cancer; 2012 Jun; 43(2):209-14. PubMed ID: 21744313
[TBL] [Abstract][Full Text] [Related]
29. Investigation of the prevalence and number of aberrant crypt foci associated with human colorectal neoplasm.
Sakai E; Takahashi H; Kato S; Uchiyama T; Hosono K; Endo H; Maeda S; Yoneda M; Taguri M; Nakajima A
Cancer Epidemiol Biomarkers Prev; 2011 Sep; 20(9):1918-24. PubMed ID: 21750169
[TBL] [Abstract][Full Text] [Related]
30. Rectal aberrant crypt foci (ACF) as a predictor of benign and malignant neoplastic lesions in the large intestine.
Kowalczyk M; Orłowski M; Klepacki Ł; Zinkiewicz K; Kurpiewski W; Kaczerska D; Pesta W; Zieliński E; Siermontowski P
BMC Cancer; 2020 Feb; 20(1):133. PubMed ID: 32075595
[TBL] [Abstract][Full Text] [Related]
31. Leukotriene Receptor Antagonist Therapy for the Chemoprevention of Human Rectal Aberrant Crypt Foci: Nonrandomized, Open-Label, Controlled Trial.
Higurashi T; Ashikari K; Tamura S; Saigusa Y; Takatsu T; Misawa N; Yoshihara T; Matsuura T; Fuyuki A; Ohkubo H; Kessoku T; Hosono K; Yoneda M; Nakajima A
Cancer Prev Res (Phila); 2022 Oct; 15(10):661-668. PubMed ID: 36083855
[TBL] [Abstract][Full Text] [Related]
32. Occurrence of colorectal aberrant crypt foci depending on age and dietary patterns of patients.
Kowalczyk M; Orłowski M; Siermontowski P; Mucha D; Zinkiewicz K; Kurpiewski W; Zieliński E; Kowalczyk I; Pedrycz A
BMC Cancer; 2018 Feb; 18(1):213. PubMed ID: 29466973
[TBL] [Abstract][Full Text] [Related]
33. Phase I pharmacokinetic study of tea polyphenols following single-dose administration of epigallocatechin gallate and polyphenon E.
Chow HH; Cai Y; Alberts DS; Hakim I; Dorr R; Shahi F; Crowell JA; Yang CS; Hara Y
Cancer Epidemiol Biomarkers Prev; 2001 Jan; 10(1):53-8. PubMed ID: 11205489
[TBL] [Abstract][Full Text] [Related]
34. Randomized, placebo-controlled trial evaluating the safety of one-year administration of green tea catechins.
Kumar NB; Pow-Sang J; Spiess PE; Park J; Salup R; Williams CR; Parnes H; Schell MJ
Oncotarget; 2016 Oct; 7(43):70794-70802. PubMed ID: 28053292
[TBL] [Abstract][Full Text] [Related]
35. Aberrant crypt foci: are they intermediate endpoints of colon carcinogenesis in humans?
Gupta AK; Schoen RE
Curr Opin Gastroenterol; 2009 Jan; 25(1):59-65. PubMed ID: 19114775
[TBL] [Abstract][Full Text] [Related]
36. Randomized, Placebo-Controlled Trial of Green Tea Catechins for Prostate Cancer Prevention.
Kumar NB; Pow-Sang J; Egan KM; Spiess PE; Dickinson S; Salup R; Helal M; McLarty J; Williams CR; Schreiber F; Parnes HL; Sebti S; Kazi A; Kang L; Quinn G; Smith T; Yue B; Diaz K; Chornokur G; Crocker T; Schell MJ
Cancer Prev Res (Phila); 2015 Oct; 8(10):879-87. PubMed ID: 25873370
[TBL] [Abstract][Full Text] [Related]
37. A Phase II Randomized, Double-blind, Presurgical Trial of Polyphenon E in Bladder Cancer Patients to Evaluate Pharmacodynamics and Bladder Tissue Biomarkers.
Gee JR; Saltzstein DR; Kim K; Kolesar J; Huang W; Havighurst TC; Wollmer BW; Stublaski J; Downs T; Mukhtar H; House MG; Parnes HL; Bailey HH
Cancer Prev Res (Phila); 2017 May; 10(5):298-307. PubMed ID: 28325826
[TBL] [Abstract][Full Text] [Related]
38. HD chromoendoscopy coupled with DNA mass spectrometry profiling identifies somatic mutations in microdissected human proximal aberrant crypt foci.
Drew DA; Devers TJ; O'Brien MJ; Horelik NA; Levine J; Rosenberg DW
Mol Cancer Res; 2014 Jun; 12(6):823-9. PubMed ID: 24651453
[TBL] [Abstract][Full Text] [Related]
39. A pilot study to evaluate the safety and efficacy of an oral dose of (-)-epigallocatechin-3-gallate-rich polyphenon E in patients with mild to moderate ulcerative colitis.
Dryden GW; Lam A; Beatty K; Qazzaz HH; McClain CJ
Inflamm Bowel Dis; 2013 Aug; 19(9):1904-12. PubMed ID: 23846486
[TBL] [Abstract][Full Text] [Related]
40. Phase 2 trial of daily, oral Polyphenon E in patients with asymptomatic, Rai stage 0 to II chronic lymphocytic leukemia.
Shanafelt TD; Call TG; Zent CS; Leis JF; LaPlant B; Bowen DA; Roos M; Laumann K; Ghosh AK; Lesnick C; Lee MJ; Yang CS; Jelinek DF; Erlichman C; Kay NE
Cancer; 2013 Jan; 119(2):363-70. PubMed ID: 22760587
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
